Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
395,158
result(s) for
"health care management"
Sort by:
Evidence-based clinical supervision
Evidence-Based Clinical Supervision critiques and summarises the best available psychological evidence relating to clinical supervision, clarifying the key principles, setting out the related practice guidelines and specifying the research and practice implications. A best-practice guide to clinical supervision, an approach used across psychotherapy and health services where professionals meet regularly with each other to discuss casework and training issues Summarises the best available clinical evidence relating to clinical supervision, and relates this information to key principles with a strong applied focus, drawing out practice guidelines and implications Aims to motivate health professionals to practice supervision with greater enthusiasm and proficiency Represents the culmination of two years' intensive research on supervision and twenty years of involvement in supporting and developing supervisors
eBook
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
eBook
Health regulation: demand and challenges of the family health strategy in an inland municipality of the State of Ceará, Brazil
This study aimed to analyze the demand profile and the challenges of regulating access to specialized care, considering the referenced cases and the perspectives of physicians in the Family Health Strategy (FHS). This was a mixed methods study, with a quantitative and qualitative approach, carried out in an inland municipality of the state of Ceará, Brazil. Quantitative data were obtained from Primary Health Care (PHC) referral forms, registered with the regulation center. Focus groups were held, involving 13 FHS physicians. The results showed 643 referrals, the majority (74.2%) corresponded to the request for tests, and 61.6% did not have a diagnostic hypothesis, which corroborates the increase in waiting time. Spine tomography was the exam with the highest amount in relation to the shortest waiting time. Regarding consultation, otorhinolaryngology was the specialty with the highest demand (17.7%). Physicians reported weaknesses and challenges in regulation, such as communication failures and the lack of counter-referral flows, which compromise Primary Health Care coordination, continuity and resolvability. The need to reorganize and qualify the regulatory processes in the municipality is pointed out.
Journal Article
Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries
Background Dementia is the most common cause of functional decline among elderly people and is associated with high costs of national healthcare in European countries. With increasing functional and cognitive decline, it is likely that many people suffering from dementia will receive institutional care in their lifetime. To delay entry to institutional care, many European countries invest in home and community based care services. Objectives This study aimed to compare costs for people with dementia (PwD) at risk for institutionalization receiving professional home care (HC) with cost for PwD recently admitted to institutional long-term nursing care (ILTC) in eight European countries. Special emphasis was placed on differences in cost patterns across settings and countries, on the main predictors of costs and on a comprehensive assessment of costs from a societal perspective. Methods Interviews using structured questionnaires were conducted with 2,014 people with dementia and their primary informal caregivers living at home or in an ILTC facility. Costs of care were assessed with the resource utilization in dementia instrument. Dementia severity was measured with the standardized mini mental state examination. ADL dependence was assessed using the Katz index, neuropsychiatrie symptoms using the neuropsychiatrie inventory (NPI) and comorbidities using the Charlson. Descriptive analysis and multivariate regression models were used to estimate mean costs in both settings. A log link generalized linear model assuming gamma distributed costs was applied to identify the most important cost drivers of dementia care. Results In all countries costs for PwD in the HC setting were significantly lower in comparison to ILTC costs. On average ILTC costs amounted to 4,491 Euro per month and were 1.8 fold higher than HC costs (2,491 Euro). The relation of costs between settings ranged from 2.4 (Sweden) to 1.4 (UK). Costs in the ILTC setting were dominated by nursing home costs (on average 94 %). In the HC setting, informal care giving was the most important cost contributor (on average 52 %). In all countries costs in the HC setting increased strongly with disease severity. The most important predictor of cost was ADL independence in all countries, except Spain and France where NPI severity was the most important cost driver. A standard deviation increase in ADL independence translated on average into a cost decrease of about 22 %. Conclusion Transition into ILTC seems to increase total costs of dementia care from a societal perspective. The prevention of long-term care placement might be cost reducing for European health systems. However, this conclusion depends on the country, on the valuation method for informal caregiving and on the degree of impairment.
Journal Article
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
Background
Self-regulation of payment disclosure by pharmaceutical industry trade groups is a major global approach to increasing transparency of financial relationships between drug companies and healthcare professionals and organisations. Nevertheless, little is known about the relative strengths and weaknesses of self-regulation across countries, especially beyond Europe. To address this gap in research and stimulate international policy learning, we compare the UK and Japan, the likely strongest cases of self-regulation of payment disclosure in Europe and Asia, across three dimensions of transparency: disclosure rules, practices, and data.
Results
The UK and Japanese self-regulation of payment disclosure had shared as well unique strengths and weaknesses. The UK and Japanese pharmaceutical industry trade groups declared transparency as the primary goal of payment disclosure, without, however, explaining the link between the two. The rules of payment disclosure in each country provided more insight into some payments but not others. Both trade groups did not reveal the recipients of certain payments by default, and the UK trade group also made the disclosure of some payments conditional on recipient consent. Drug company disclosure practices were more transparent in the UK, allowing for greater availability and accessibility of payment data and insight into underreporting or misreporting of payments by companies. Nevertheless, the share of payments made to named recipients was three times higher in Japan than in the UK, indicating higher transparency of disclosure data.
Conclusions
The UK and Japan performed differently across the three dimensions of transparency, suggesting that any comprehensive analysis of self-regulation of payment disclosure must triangulate analysis of disclosure rules, practices, and data. We found limited evidence to support key claims regarding the strengths of self-regulation, while often finding it inferior to public regulation of payment disclosure. We suggest how the self-regulation of payment disclosure in each country can be enhanced and, in the long run, replaced by public regulation to strengthen the industry’s accountability to the public.
Journal Article